How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/rectal-chlamydia-trachomatis-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rectal Chlamydia Trachomatis Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rectal Chlamydia Trachomatis Infection (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rectal Chlamydia Trachomatis Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Benzamycin	Erythromycin Lactobionate	Pfizer	Macrolide	Potassium voltage-gated channel subfamily H member 2	1964-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
E-Mycin	erythromycin	Generic (originally Abbott/Lilly)	Macrolide [EPC]	Aldehyde oxidase, Bile salt export pump, Cytochrome P450 1B1	1952-01-01
Doxycyclin	Doxycyclin	Bulovka Hospital		72 kDa type IV collagenase, Stromelysin-1, Collagenase 3
Minocyclin	Minocyclin	University of Southern California		30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Rectal Chlamydia Trachomatis Infection
Astellas Pharma · 1 drug in Rectal Chlamydia Trachomatis Infection
Bulovka Hospital · 1 drug in Rectal Chlamydia Trachomatis Infection
Generic (originally Abbott/Lilly) · 1 drug in Rectal Chlamydia Trachomatis Infection
Generic (originally Pfizer) · 1 drug in Rectal Chlamydia Trachomatis Infection
Pfizer · 1 drug in Rectal Chlamydia Trachomatis Infection
Rempex · 1 drug in Rectal Chlamydia Trachomatis Infection
University of Southern California · 1 drug in Rectal Chlamydia Trachomatis Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rectal Chlamydia Trachomatis Infection:

Cite this brief

Drug Landscape (2026). Rectal Chlamydia Trachomatis Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rectal-chlamydia-trachomatis-infection. Accessed 2026-06-10.

Rectal Chlamydia Trachomatis Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing